Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
| 473.09 Delayed Data As of Apr 12 |  -2.37 / -0.50%Today’s Change | 441.00 Today|||52-Week Range 664.64 | -2.07% Year-to-Date |
Latest REGN News | Press Releases
| Founders Capital Management, Llc Buys Apple Inc, Merck Inc, International Flavors & ... Apr 12 / GuruFocus News - Paid Partner Content | Private Trust Co Na Buys Target Corp, Lam Research Corp, Roper Technologies Inc, Sells Vanguard ... Apr 06 / GuruFocus News - Paid Partner Content |
| Regeneron (REGN) Posts Positive Data on COVID-19 Antibody Cocktail Apr 12 / Zacks.com - Paid Partner Content | 3 Stocks Cathie Wood Is Selling That Long-Term Investors Should Be Buying Apr 06 / MotleyFool.com - Paid Partner Content |
| Old Port Advisors Buys iShares TIPS Bond ETF, iShares MBS ETF, iShares Mortgage Real Estate ... Apr 08 / GuruFocus News - Paid Partner Content | CytoDyn (CYDY) Files New Protocol With FDA for COVID-19 Study Apr 01 / Zacks.com - Paid Partner Content |
| 3 Top Biotech Stocks to Buy in April Apr 07 / MotleyFool.com - Paid Partner Content | Could Regeneron's Antibody Therapy Be as Important as Vaccines in Fighting COVID? Mar 31 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 475.17 |
| Today’s open | 481.78 |
| Day’s range | 469.80 - 481.78 |
| Volume | 835,612 |
| Average volume (3 months) | 1,007,101 |
| Market cap | $50.9B |
Data as of 4:00pm ET, 04/12/2021
Growth & Valuation
| Earnings growth (last year) | +68.51% |
| Earnings growth (this year) | +48.06% |
| Earnings growth (next 5 years) | +1.50% |
| Revenue growth (last year) | +8.06% |
| P/E ratio | 15.5 |
| Price/Sales | 6.54 |
| Price/Book | 4.61 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TAKTakeda Pharmaceutica... | -0.00 | -0.03% |
| VRTXVertex Pharmaceutica... | +0.25 | +0.12% |
| ---- | ||
| ---- |
Data as of 4:00pm ET, 04/12/2021
Financials
| Next reporting date | May 6, 2021 |
| EPS forecast (this quarter) | $10.12 |
| Annual revenue (last year) | $8.5B |
| Annual profit (last year) | $3.5B |
| Net profit margin | 41.35% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Tarrytown, New York |
Forecasts
